Therapeutic Macrolide Compounds and Their Use

A compound selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:

• wherein:
• —R7 is independently —OH, —OR7A, or —O—C(O)R7A
• wherein:
• —R7A is independently —R7A1, —R7A2 or —R7A3
• wherein:
• —R7A1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —R7A2 is independently saturated or unsaturated alicyclic or aromatic C3-20carbocyclyl, and is optionally substituted
• and wherein:
• —R7A3 is independently —NH2, —NHR7NA, —N(R7NA)2, or —NR7NBR7NC
• wherein:
• each —R7NA is independently —R7NA1 or —R7NA2
• wherein:
• —R7NA1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —R7NA2 is independently saturated or unsaturated alicyclic or aromatic, carbo or hetero, C3-20cyclyl, and is optionally substituted
• and wherein:
• —NR7NBR7NC is independently saturated or unsaturated alicyclic or aromatic C3-20heterocyclyl, and is optionally substituted
• and wherein:
• —X16 is independently —OR16A or —NR16AR16B
• wherein:
• R16A is independently —H, —Z16A, —Y16AZ16A or together with —R17A is -L-
• wherein:
• —Y16A— is independently saturated or unsaturated aliphatic C1-4 alkylene, and is optionally substituted
• and wherein:
• -L- is independently saturated or unsaturated aliphatic C1-4 alkylene, —S(O)(O)— or —C(O)—, and is optionally substituted
• and wherein:
• —Z16A is independently —Z16A1 or —Z16A2
• wherein:
• —Z16A1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —Z16A2 is independently saturated or unsaturated alicyclic or aromatic C3-20cyclyl, and is optionally substituted
• and wherein:
• R16B is independently —H, —Z16B or —Y16BZ16B
• wherein:
• —Y16B— is independently saturated or unsaturated aliphatic C1-4 alkylene, and is optionally substituted
• and wherein:
• —Z16B is independently —Z16B1 or —Z16B2
• wherein:
• —Z16B1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —Z16B2 is independently saturated or unsaturated alicyclic or aromatic C3-20cyclyl, and is optionally substituted
• and wherein:
• —X17 is independently —NR17AR17B
• wherein:
• —R17A is independently —H, —Z17A, —Y17AZ17A or together with —R16A is -L-
• wherein:
• —Y17A— is independently saturated or unsaturated aliphatic C1-4 alkylene, —C(O)—, or —S(O)(O)—, and is optionally substituted
• and wherein:
• -L- is independently as defined above
• and wherein:
• —Z17A is independently —Z17A1 or —Z17A2
• wherein:
• —Z17A1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —Z17A2, if present, is independently —Z17AH or —Z17AC
• wherein:
• —Z17AH is saturated or unsaturated alicyclic or aromatic C3-20heterocyclyl, and is optionally substituted
• and wherein:
• —Z17AC is saturated or unsaturated alicyclic or aromatic C3-20carbocyclyl, and is optionally substituted
• and wherein:
• —R17B is independently —H, —Z17B or —Y17BZ17B,
• wherein:
• —Y17B— is independently saturated or unsaturated aliphatic C1-4 alkylene, —C(O)—, or —S(O)(O)—, and is optionally substituted
• and wherein:
• —Z17B is independently —Z17B1, —Z17B2 or —Z17B3.
• wherein:
• —Z17B1 is independently saturated or unsaturated aliphatic C1-6alkyl, and is optionally substituted
• and wherein:
• —Z17B2 is independently saturated or unsaturated alicyclic or aromatic C3-20carbocyclyl, and is optionally substituted
• and wherein:
• —Z17B3 is independently saturated or unsaturated alicyclic or aromatic C3-20heterocyclyl, and is optionally substituted
• and wherein:
• —R21 is independently —H or -Me.